The Hypothyroidism drugs in development market research report provides comprehensive information on the therapeutics under development for Hypothyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hypothyroidism. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hypothyroidism and features dormant and discontinued products.

GlobalData tracks eight drugs in development for Hypothyroidism by eight companies/universities/institutes. The top development phase for Hypothyroidism is phase ii with four drugs in that stage. The Hypothyroidism pipeline has eight drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hypothyroidism pipeline products market are: Xeris Biopharma, AbbVie and Synthonics.

The key targets in the Hypothyroidism pipeline products market include Thyroid Hormone Receptor Beta (Nuclear Receptor Subfamily 1 Group A Member 2 or c erbA 2 or c erbA Beta or ERBA2 or THRB), Thyroid Hormone Receptor Alpha (Nuclear Receptor Subfamily 1 Group A Member 1 or V erbA Related Protein 7 or c erbA 1 or c erbA Alpha or EAR7 or THRA), and Thyroid Hormone Receptor.

The key mechanisms of action in the Hypothyroidism pipeline product include Thyroid Hormone Receptor Alpha (Nuclear Receptor Subfamily 1 Group A Member 1 or V erbA Related Protein 7 or c erbA 1 or c erbA Alpha or EAR7 or THRA) Agonist with four drugs in Phase II. The Hypothyroidism pipeline products include two routes of administration with the top ROA being Oral and one key molecule types in the Hypothyroidism pipeline products market including Small Molecule.

Hypothyroidism overview

Hypothyroidism (underactive thyroid) is a condition in which the thyroid gland doesn’t produce enough of certain important hormones. Signs and symptoms include fatigue, constipation, dry skin, puffy face, muscle weakness, muscle aches, tenderness and stiffness, pain, and stiffness. Risk factors include autoimmune diseases, thyroid surgery, radiation therapy, and family history of thyroid disease.

For a complete picture of Hypothyroidism’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.